Clinical trial
A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants)
NCT00679744 is registered in ClinicalTrials.gov with Exsar Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants)
- Lead sponsor
- Exsar Corporation
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- May 31, 2008
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
g(m2) ganglioside, sandhoff disease ganglioside, tay-sachs disease ganglioside